Related content

Infusional Mitoxantrone Plus Bolus Melphalan as a Stem Cell Transplant Conditioning Regimen for Multiple Myeloma

By Beaven Anne W.   Moore Dominic T.   Sharf Andrew   Serody Jonathan S.   Shea Thomas C.   Gabriel Don A.  

Cancer Investigation, Vol. 29, Iss. 3, 2011-02 ,pp. : 214-219

Informa Healthcare

Access to resources Recommend Favorite

Health-Related Quality of Life in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Blood Stem-Cell Support

By Gulbrandsen N.   Wisløff F.   Brinch L.   Carlson K.   Dahl I.M.   Gimsing P.   Hippe E.   Hjorth M.   Knudsen L.M.   Lamvik J.   Lenhoff S.   Løfvenberg E.   Nesthus I.   Lanng Nielsen J.   Turesson I.   Westin J.  

Medical Oncology, Vol. 18, Iss. 1, 2001-03 ,pp. : 65-77

Humana Press, Inc

Access to resources Recommend Favorite

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

By Wong Doo Nicole  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1465-1472

Informa Healthcare

Access to resources Recommend Favorite

Double high-dose chemotherapy and stem cell transplantation in adult Wilms’ tumor

By Kosmas Christos   Daladimos Theodoros   Athanasopoulos Aggelos   Theotikos Evangelos   Tsakonas George   Karabelis Athanasios   Mylonakis Nikolaos  

Future Oncology, Vol. 6, Iss. 11, 2010-11 ,pp. : 1803-1809

Future Medicine

Access to resources Recommend Favorite

High-Dose Topotecan, Melphalan, and Cyclophosphamide (TMC) with Stem Cell Support: A New Regimen for the Treatment of Advanced Ovarian Cancer

By Donato M.L.   Gershenson D.M.   Wharton J.T.   Ippoliti C.M.   Aleman A.S.   Bodurka-Bevers D.   Bevers M.W.   Burke T.W.   Levenback C.F.   Wolf J.K.   Freedman R.S.   Bast R.C.   Gajewski J.L.   Champlin R.E.  

Gynecologic Oncology, Vol. 82, Iss. 3, 2001-09 ,pp. : 420-426

Elsevier

Access to resources Recommend Favorite